SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).

被引：0

作者：

Garland, Linda L.

Ou, Sai-Hong

Moon, James

Mack, Philip C.

Testa, Joseph

Tsao, Anne S.

Wozniak, Antoinette J.

Gandara, David R.

机构：

[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA

[2] UC Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Orange, CA USA

[3] Southwest Oncol Grp Stat Ctr, Seattle, WA USA

[4] Univ Calif Davis, Sacramento, CA 95817 USA

[5] Fox Chase Canc Ctr, Buckingham, PA USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[8] UC Davis Canc Ctr, Div Hematol & Oncol, Sacramento, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7083

引用

页数：1

共 50 条

[21] A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies.
Yee, KWL
Wierda, W
O'Brien, S
Thomas, D
Kurzrock, R
Fayad, LE
Hagemeister, FB
Cortes, J
Prestifilippo, K
Szatrowski, TP
Kantarjian, HM
Giles, FJ
BLOOD, 2004, 104 (11) : 287B - 287B
[22] The mTOR inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo
Mitsiades, N
McMullan, C
Poulaki, V
Negri, J
Raje, N
Kumar, S
Sikoutri, D
Hideshima, T
Chauhan, D
Richardson, PG
Schlossman, RL
Kung, AL
Lane, H
Munshi, NC
Anderson, KC
Mitsiades, CS
BLOOD, 2004, 104 (11) : 418A - 418A
[23] A Phase Ib Trial of Erlotinib, an EGFR Inhibitor, and Everolimus (RAD001), an mTOR Inhibitor, in Patients with Metastatic Breast Cancer.
Mayer, I. A.
Means-Powell, J.
Shyr, Y.
Arteaga, C. L.
CANCER RESEARCH, 2009, 69 (24) : 677S - 677S
[24] The mTOR inhibitor RAD001 (Everolimus) improves survival in preclinical models of primary human ALL
Crazzolara, Roman
Cisterne, Adam
Thien, Marilyn
Hewson, John
Bradstock, Kenneth Francis
Bendall, Linda J.
BLOOD, 2007, 110 (11) : 262A - 262A
[25] Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma.
Rao, R. D.
Windschitl, H. E.
Allred, J. B.
Lowe, V. J.
Maples, W. J.
Gornet, M. K.
Suman, V. J.
Creagan, E. T.
Pitot, H. C.
Markovic, S. N.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 463S - 463S
[26] Analysis of the mTOR signaling pathway versus proliferative response of tumor cells to the mTOR inhibitor RAD001 (everolimus)
Breuleux, M.
Zumstein-Mecker, S.
O'Reilly, T.
Natt, F.
Maira, M.
Lane, H.
EJC SUPPLEMENTS, 2006, 4 (12): : 181 - 181
[27] Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium
Milowsky, M. I.
Regazzi, A. M.
Garcia-Grossman, I. R.
Trout, A.
Flaherty, A.
Gerst, S.
Bajorin, D. F.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
[28] The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer:: Results of a phase I study with pharmacokinetics
Awada, Ahmad
Cardoso, Fatima
Fontaine, Christel
Dirix, Luc
De Greve, Jacques
Sotiriou, Christos
Steinseifer, Jutta
Wouters, Carine
Tanaka, Chiaki
Zoellner, Ulrike
Tang, Pui
Piccart, Martine
EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 84 - 91
[29] Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.
Ghobrial, Irene M.
Gertz, Morie A.
LaPlant, Betsy
Camoriano, John Kelly
Hayman, Suzanne R.
Lacy, Martha
Chuma, Stacey
Harris, Brianna
Boswell, Erica
Banwait, Ranjit
Sheehy, Patricia
Ansell, Stephen Maxted
DeAngelo, Daniel J.
Dispenzieri, Angela
Bergsagel, Leif
Reeder, Craig B.
Anderson, Kenneth Carl
Richardson, Paul Gerard Guy
Treon, Steven P.
Witzig, Thomas E.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[30] Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium
Milowsky, M. I.
Trout, A.
Regazzi, A. M.
Garcia-Grossman, I.
Flaherty, A.
Tickoo, S.
Al-Ahmadie, H.
Bajorin, D. F.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →